Profund Advisors LLC Nektar Therapeutics Transaction History

Profund Advisors LLC

$2.52 Billion
Q1 2024

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 11, 2023	SELL	$0.64 - $3.15 $853 - $4,198	-1,333 Reduced 10.06%	11,912 $8,000
Q4 2022 Feb 02, 2023	SELL	$2.03 - $4.28 $2,168 - $4,571	-1,068 Reduced 7.46%	13,245 $29,000
Q3 2022 Nov 04, 2022	SELL	$3.04 - $5.14 $68,971 - $116,616	-22,688 Reduced 61.32%	14,313 $46,000
Q2 2022 Aug 01, 2022	SELL	$3.17 - $6.17 $4,865 - $9,470	-1,535 Reduced 3.98%	37,001 $141,000
Q1 2022 May 10, 2022	BUY	$4.16 - $13.72 $1,709 - $5,638	411 Added 1.08%	38,536 $208,000

Q4 2021 Feb 08, 2022	SELL	$10.83 - $18.41 $1,299 - $2,209	-120 Reduced 0.31%	38,125 $515,000
Q3 2021 Nov 12, 2021	SELL	$13.07 - $18.84 $37,367 - $53,863	-2,859 Reduced 6.96%	38,245 $687,000
Q2 2021 Aug 12, 2021	SELL	$16.52 - $20.4 $12,951 - $15,993	-784 Reduced 1.87%	41,104 $704,000
Q1 2021 May 14, 2021	SELL	$16.56 - $25.46 $63,540 - $97,690	-3,837 Reduced 8.39%	41,888 $838,000
Q4 2020 Feb 09, 2021	BUY	$15.77 - $19.03 $60,809 - $73,379	3,856 Added 9.21%	45,725 $777,000
Q3 2020 Nov 13, 2020	SELL	$16.59 - $24.79 $76,247 - $113,934	-4,596 Reduced 9.89%	41,869 $695,000
Q2 2020 Aug 03, 2020	BUY	$16.86 - $23.44 $126,686 - $176,128	7,514 Added 19.29%	46,465 $1.08 Million
Q1 2020 May 15, 2020	SELL	$14.47 - $27.96 $250,099 - $483,260	-17,284 Reduced 30.74%	38,951 $695,000
Q4 2019 Feb 18, 2020	BUY	$15.87 - $23.12 $221,973 - $323,379	13,987 Added 33.11%	56,235 $1.21 Million
Q3 2019 Nov 12, 2019	SELL	$16.91 - $36.27 $48,717 - $104,493	-2,881 Reduced 6.38%	42,248 $770,000
Q2 2019 Aug 13, 2019	SELL	$31.0 - $36.3 $154,411 - $180,810	-4,981 Reduced 9.94%	45,129 $1.61 Million
Q1 2019 May 15, 2019	BUY	$31.58 - $46.35 $38,369 - $56,315	1,215 Added 2.48%	50,110 $1.68 Million
Q4 2018 Feb 14, 2019	SELL	$30.43 - $56.65 $386,643 - $719,794	-12,706 Reduced 20.63%	48,895 $1.61 Million
Q3 2018 Nov 13, 2018	BUY	$46.46 - $68.49 $428,082 - $631,066	9,214 Added 17.59%	61,601 $3.76 Million
Q2 2018 Aug 13, 2018	SELL	$46.25 - $104.45 $382,395 - $863,592	-8,268 Reduced 13.63%	52,387 $2.56 Million
Q1 2018 May 14, 2018	SELL	$57.4 - $108.44 $1.16 Million - $2.2 Million	-20,282 Reduced 25.06%	60,655 $6.45 Million
Q4 2017 Feb 14, 2018	SELL	$23.02 - $60.5 $152,139 - $399,844	-6,609 Reduced 7.55%	80,937 $4.83 Million
Q3 2017 Nov 13, 2017	BUY	$17.79 - $24.0 $1.09 Million - $1.46 Million	60,996 Added 229.74%	87,546 $2.1 Million
Q2 2017 Aug 11, 2017	BUY	N/A	26,550	26,550 $519,000

Others Institutions Holding NKTR

# of Institutions

128

Shares Held

111M

Call Options Held

150K

Put Options Held

Deep Track Capital, LP Greenwich, CT

18.4M
Shares

$21.5 Million
0.57% of portfolio
Vanguard Group Inc Valley Forge, PA

12M
Shares

$14.1 Million
0.0% of portfolio
Acadian Asset Management LLC Boston, MA

7.57M
Shares

$8.86 Million
0.02% of portfolio
Primecap Management CO Pasadena, CA

6.97M
Shares

$8.15 Million
0.0% of portfolio
Black Rock Inc. New York, NY

5.88M
Shares

$6.88 Million
0.0% of portfolio

View Full List

About NEKTAR THERAPEUTICS

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $219M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

More about NKTR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Profund Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Profund Advisors LLC with notifications on news.

Account